Thus, given the significant potential of IDO1 and Pyk2 as therapeutic targets for breast cancer, further clinical studies are necessary to validate their potential applications in predicting the potential response of CCB to combination immunotherapy. This evidence concerns the gene PTK2B and breast carcinoma.